About FibrosIX
Fibrosis encompasses a myriad of diseases that can result in morbidity and contributes to the majority of all deaths.
At FibrosIX, we are preventing fibrosis through innovative therapeutics.
FibrosIX is a pre-clinical stage biotechnology start-up, founded in 2016. It is developing proprietary first-in-class small-molecule therapeutics that inhibit fibrotic disease. These drugs modulate a critical signaling pathway that plays a central role in the pathogenesis of fibrotic disease.
The lead drug candidate, FBX081, is being developed for the prevention of lung fibrosis in cancer patients induced by chemotherapy (bleomycin) and/or radiation therapy.
Watch the Introduction to Fibrosix Video
fibrosis
[fahy-broh-sis]
noun Pathology.
the thickening and scarring of connective tissue, usually as a result of injury.
ORIGIN
late 19th century from Latin fibra + -osis
FibrosIX
[fahy-broh-six]
noun Pre-clinical stage biotechnology start-up.
a company dedicated to preventing fibrosis through innovative therapeutics.
ORIGIN
founded in 2016, Lansing, Michigan
Latest News from FibrosIX
FibrosIX Inc. Awarded Competitive Grant from the National Science Foundation
Small Business Innovation Research Program Provides Seed Funding for R&D East Lansing, Michigan, March 1, 2021 – FribrosIX has been [...]
FibrosIX Inc. SBIR grant from the National Science Foundation
FibrosIX Inc. has been awarded a National Science Foundation (NSF) SBIR grant to explore the ability of our compounds to [...]
Starting the New Year off right
From the team at FibrosIX Inc, we would like to wish everyone a happy and safe start to 2021! After [...]